**Suppl. Table 4. Comparison of clinico-pathological features based on treatment response**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Remission (n=30) | No remission (n=33) | *P* value |
| Male/female | 17/13 | 24/9 | 0.182 |
| Age(mean±s.d.), yr | 37±11 | 35±12 | 0.553 |
| MAP, mmHg | 108±19 | 115±18 | 0.220 |
| PLT,109/L | 176±128 | 158±84 | 0.630 |
| Hb,g/L | 99±30 | 95±37 | 0.470 |
| Hypocomplementemia, n(%)a | 7(23.3) | 11(33.3) | 0.380 |
| LDH, IU/Lb | 844±1174 | 520±645 | 0.811 |
| Proteinuria(mean±s.d.), g/dc | 2.3±2.7 | 2.7±2.1 | 0.199 |
| eGFR (mean±s.d.), ml/min per 1.73 m2 | 38.0±27.1 | 34.7±33.7 | 0.205 |
| FPW(nm) | 925±344 | 1240±793 | **0.013** |
| Glomerular TMA |  |  |  |
| Endothelial cell swelling and proliferation | 1(0-1) | 1(0-1) | 0.899 |
| Mesangiolysis | 0(0-0) | 0(0-0) | 0.102 |
| Capillary fibrinoid necrosis and/or thrombi | 0(0-0) | 0(0-0) | 0.791 |
| GBM double contours | 0.5(0-1) | 0(0-1) | 0.752 |
| Mesangial proliferation | 1(0-1) | 0(0-1) | 0.286 |
| Global and segmental glomerulosclerosis | 1(1-2) | 1(1-2) | 0.878 |
| Subendothelial zone widening on EM | 1(0-1.25) | 1(1-2) | 0.090 |
| Arteriolar and arterial TMA |  |  |  |
| Thrombi | 0(0-0) | 0(0-0) | 0.886 |
| Endothelial cell swelling and subintimal myxiod edema | 1(0-2.25) | 2(1-3) | **0.006** |
| Arteriolar fibrinoid necrosis | 0(0-0) | 0 | 0.340 |
| Onion skin lesions | 1(0-3) | 2(1-3) | 0.297 |
| Arteriolar hyalinosis | 0(0-1) | 0(0-0) | 0.168 |
| Tubulointerstitial lesions |  |  |  |
| Tubular atrophy/Interstitial fibrosis | 2(1-3) | 3(1-3) | 0.134 |
| Scoring of pathological variables was expressed as median (interquartile range).Abbreviations: MAP, mean arterial pressure; PLT, platelet; Hb, hemoglobin; LDH, lactate dehydrogenase; eGFR, estimated glomerular filtration rate; FPW, foot process width; TMA, thrombotic microangiopathy; EM, electron microscopy; GBM, glomerular basement membrane.  aExcluding 7 individuals with no information on C3 level at onset.  bExcluding 21 individuals without information on LDH at onset.  cExcluding 2 individuals without information on proteinuria at onset. | | | |